Why the study?
Does influenza vaccine reduce major adverse cardiovascular events in high-risk patients?
Does influenza vaccine reduce major adverse cardiovascular events in high-risk patients?
Influenza vaccination is associated with a reduced risk of major adverse cardiovascular events, particularly in high-risk patients with active coronary disease.
Supports influenza vaccination in high-risk coronary patients; confirms MACE reduction and extends evidence to those with active disease.
In a meta-analysis of RCTs, the use of influenza vaccine was associated with a lower risk of major adverse cardiovascular events. The greatest treatment effect was seen among the highest-risk patients with more active coronary disease. A large, adequately powered, multicenter trial is warranted to address these findings and assess individual cardiovascular end points.
No takes yet. Share an insight, caveat, or question.
Udell et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: